Revvity said it now expects its full-year 2025 adjusted earnings per share to exceed the high end of the range it provided in October of $4.90 to $5.00. Management cited robust demand for its contract research and diagnostics services as the primary driver. The company’s CFO highlighted that strengthening volumes in bioanalytical testing and renewed bookings in its pharmaceutical services segment have more than offset headwinds from foreign currency fluctuations and supply–chain costs.

In its earnings release dated today, Revvity provided preliminary financial metrics ahead of its February 2 call. Fourth quarter revenue is expected to reach approximately $772 million, up 6% reported and 4% on an organic basis versus the prior year. For the full year, total revenue is forecast at around $2,855 million, representing reported growth of 4% and organic growth of 3%. Management attributed organic gains to higher uptake of its multi-omics platforms and expanded diagnostic lab agreements in North America and Europe.

Revvity and Eli Lilly announced a collaboration to integrate Revvity’s TuneLab AI drug-discovery models into Lilly’s Signals Xynthetica federated platform. The partnership aims to accelerate preclinical candidate screening while maintaining data security across multiple research sites. Revvity CEO Prahlad Singh said the deal strengthens the company’s informatics offerings and positions it to capture a larger share of the emerging AI-driven discovery market.